Article
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
Clinical lung cancer - 1 Jan 2016
Hotta Katsuyuki, Sasaki Jiichiro, Saeki Sho, Takigawa Nagio, Katsui Kuniaki, Takayama Koichi, Nogami Naoyuki, Shioyama Yoshiyuki, Bessho Akihiro, Kishimoto Junji, Tanimoto Mitsune, Kiura Katsuyuki, Ichinose Yukito
Abstract excerpt
Herein, we describe an ongoing phase II trial in patients with locally advanced non-small-cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR). Patients with chemotherapy-naive locally advanced disease with active EGFR mutations will receive the induction treatment, specified as gefitinib monotherapy (250 mg/body) for 8 weeks. Patients whose disease has not progressed during the induction...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.